{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-023666","form_type":"8-K","ticker":"VYCO","cik":"0001424768","company_name":"VYCOR MEDICAL INC","filed_at":"2026-05-15T19:42:28+00:00","discovered_at":"2026-05-15T19:44:04.379121+00:00","generated_at":"2026-05-15T19:45:11.318813+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Vycor Medical Q1 2026 revenue up 5% to $458,540; turns to operating profit of $45,808","bullets":["Revenue $458,540 (+5% YoY); Vycor Medical division contributed $440,441.","Operating profit of $45,808 vs operating loss of $(12,806) in Q1 2025.","Non-GAAP operating profit $59,788, up from $20,388 YoY; cash expenses down to $315,365.","Gross margin steady at 82% for Vycor Medical; two new peer-reviewed VBAS studies published.","NovaVision revenue $18,099, still in development stage."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-023666","json":"https://secwatch.observer/filing/0001493152-26-023666.json","markdown":"https://secwatch.observer/filing/0001493152-26-023666.md","text":"https://secwatch.observer/filing/0001493152-26-023666.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1424768/000149315226023666/0001493152-26-023666-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1424768/000149315226023666/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:45:11.318813+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bcb1002690c8a55af044a99a08a3ae8b09a3795a","claim":"VYCOR MEDICAL INC reported the three months ended March 31, 2026 results: revenue $458,540.","evidence_excerpt":"the traditional blade retractor group, implying safer tumor resection using VBAS. Financial Results For the three months ended March 31, 2026, the Company reported revenue of $458,540, an increase of $22,162 (or 5%) over the 2025 period. The Vycor Medical division (VBAS) generated revenue of $440,441, an increase of $21,921 (or 5%) over the 2025 period. Most of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1424768/000149315226023666/0001493152-26-023666-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2026"},{"label":"Revenue","value":"$458,540"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}